Letter: tricky reactions to switch back from subcutaneous to intravenous vedolizumab in inflammatory bowel disease patients-authors' reply

Adriaan Volkers,Tessa Straatmijer,Marjolijn Duijvestein,Mark Lowenberg,Andrea van Der Meulen,Geert D'Haens

ALIMENTARY PHARMACOLOGY & THERAPEUTICS（2023）

引用 1|浏览8

暂无评分

摘要

LINKED CONTENT This article is linked to Volkers et al papers. To view these articles, visit https://doi.org/10.1111/apt.17153 and https://doi.org/10.1111/apt.17395

查看译文

关键词

intravenous vedolizumab,inflammatory bowel disease,inflammatory bowel disease patients—authors

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要